The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C - A critical review

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 2044-2063

  Chan, Alice H W ^a,b   Partovi, Nilufar ^a   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Clinical pharmacokinetic monitoring; Drug levels; Hepatitis C; Ribavirin; Therapeutic monitoring

Indexed keywords

ALPHA2 INTERFERON; ALPHA2B INTERFERON; AMIDE; HEMOGLOBIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN; VIRUS RNA;

ALGORITHM; ANEMIA; BIBLIOGRAPHIC DATABASE; BIOSIS; CAPILLARY ELECTROPHORESIS; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMORBIDITY; CREATININE CLEARANCE; DECISION MAKING; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MONITORING; DRUG RESPONSE; DRUG WITHDRAWAL; EMBASE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LANGUAGE; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; MASS SPECTROMETRY; MEDLINE; MIXED INFECTION; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 72249104236     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M225     Document Type: Review

References (87)

1. Wasley A, Grytdal S, Gallagher K, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2006. MMWR Surveill Summ 2008;57:1-24.
2. Hepatitis C. Ottawa, ON: Public Health Agency of Canada. www.phacaspc. gc.ca/hepc/index-e.html (accessed 2008 Mar 30).
3. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S-7S.
4. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171
5. Wong T, Lee S. Hepatitis C: a review for primary care physicians. CMAJ 2006;174:649-659
6. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;46:563-570 (Pubitemid 28522120)
7. Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003;63:701-730
8. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-1632
9. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004. (Pubitemid 30169949)
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965 (Pubitemid 32913521)
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
12. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-981 (Pubitemid 350144761)
13. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastro Hepatol 2007;5:124-129
14. Reddy R, Dieterich DT, Hadziyannis SJ, Messinger D, Fried MW. Multiple logistic regression analysis identifies ribavirin as a modifiable and independent predictor of relapse amongst chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin (poster 1283). Presented at: The Liver Meeting 2008: 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, October 31-November 4, 2008.
15. Oze T, Hiramatsu N, Yakushijin T, et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with chronic hepatitis C responding to pegylated interferon alfa-2b plus ribavirin (poster 1238). Presented at: The Liver Meeting 2008: 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, October 31-November 4, 2008.
16. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008;62:1174-1180
17. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34:265-279
18. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007;21(suppl C):25C-34C. (Pubitemid 47177083)
19. Gish RG, Arora S, Rajender Reddy K, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007;47:51-59 (Pubitemid 46817694)
20. Benhamou Y, Pockros P, Rodrieuez-Torres M, et al. The safety and efficacy of viramidine plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results (abstract 751). J Hepatol 2006;44(suppl 2):S273.
21. Marcellin P, Lurie Y, Rodrigues-Torres M, Chasen R, Xu Y, Murphy B. The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naive patients infected with HCV: Phase 3 results (abstract 10). J Hepatol 2007;46(suppl 1):S7.
22. Austin RK, Trefts PE, Hintz M, Connor JD, Kagnoff MF. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother 1983;24:696-701. (Pubitemid 14203868)
23. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003;47:124-129 (Pubitemid 36070352)
24. Svensson JO, Bruchfeld A, Schvarcz R, Stahle L. Determination of ribavirin in serum using highly selective solid-phase extraction and highperformance liquid chromatography. Ther Drug Monit 2000;22:215-218 (Pubitemid 30196828)
25. Shou WZ, Bu HZ, Addison T, Jiang X, Naidong W. Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. J Pharm Biomed Anal 2002;29:83-94. (Pubitemid 34621273)
26. Inoue Y, Homma M, Matsuzaki Y, et al. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 2004;48:3813-3816 (Pubitemid 39304608)
27. Breadmore MC, Theurillat R, Thormann W. Determination of ribavirin in human serum and plasma by capillary electrophoresis. Electrophoresis 2004;25:1615-1622 (Pubitemid 38885825)
28. Morello J, Rodriguez-Novoa S, Cantillano AL, Gonzalez-Pardo G, Jimenez I, Soriano V. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007;29:802-806 (Pubitemid 350190858)
29. Homma M, Jayewardene AL, Gambertoglio J, Aweeka F. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob Agents Chemother 1999;43:2716-2719 (Pubitemid 29519553)
30. Paroni R, Sirtori CR, Borghi C, Kienle MG. High-performance liquid chromatographic determination of ribavirin in serum and urine and of its urinary metabolite 1,2,4-triazole-3-carboxamide. J Chromatogr 1987;420:189-196 (Pubitemid 17143241)
31. Yeh LT, Nguyen M, Lin CC. A sensitive and specific method for the determination of total ribavirin in human red blood cells by chromatography- tandem mass spectrometry. J Chromato Sci 2003;41:255-260
32. Granich GG, Krogstad DJ, Connor JD, Desrochers KL, Sherwood C. High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay. Antimicrob Agents Chemother 1989;33:311-315 (Pubitemid 19071962)
33. Alsio A, Westin J, Hellstrand K, Norkrans GP, Lagging M. Non-responder HCV genotype 2/3 patients: is it simply a question of suboptimal interferon and ribavirin concentrations (poster 1878). Presented at: The Liver Meeting 2008: 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, October 31-November 4, 2008.
34. Arase Y, Ikeda K, Suzuki F, et al. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004;39:1090-1094 (Pubitemid 39618793)
35. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005;48:138-144 (Pubitemid 41201504)
36. Asahina Y, Izumi N, Umeda N, et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007;14:396-403. (Pubitemid 46744048)
37. Christensen PB, Alsio AA, Buhl MR, et al. Ribavirin concentration at week four is an independent predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (NORDynamic trial). J Hepatol 2008;48(suppl 2):S6-7.
38. Donnerer J, Grahovac M, Stelzl E, et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 2006;76:136-140 (Pubitemid 43289466)
39. Inoue Y, Homma M, Matsuzaki Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006;34:23-27 (Pubitemid 43091872)
40. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-565 (Pubitemid 30744072)
41. Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002;72:349-361 (Pubitemid 35178861)
42. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin- induced anaemia. J Viral Hepat 2004;11:84-87 (Pubitemid 38221622)
43. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-279 (Pubitemid 40165370)
44. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008;47:1453-1461 (Pubitemid 351702729)
45. Maeda Y, Kiribayashi Y, Moriya T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004;26:9-15. (Pubitemid 38140904)
46. Mangia A, Dalgard O, Minerva N, et al. Ribavirin (RBV) dosage as independent predictor of RVR in HCV genotype 2 (HCV-2) and 3 (HCV-3) patients undergoing combined treatment with peg interferon (peg-IFN) alpha- 2b (abstract 630). J Hepatol 2009;50(suppl 1):S232.
47. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008;13:607-611 (Pubitemid 352016724)
48. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-982 (Pubitemid 47492337)
49. Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006;44:3562-3568 (Pubitemid 46768817)
50. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008;48:1753-1760
51. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006;62:699-709. (Pubitemid 44749547)
52. Souvignet C, Stanke-Labesque E, Bronowicki JP, Larrat S, Quesada JL, Zarsld JP. Evidence that serum ribavirin steady-state concentrations do not correlate with early virological response during peginterferon alpha- 2a plus ribavirin combination therapy for chronic hepatitis C (abstract 604). J Hepatol 2005;42(suppl 2):S221.
53. Tsubota A, Akuta N, Suzuki F, et al. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002;45:33-42. (Pubitemid 34293700)
54. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003;55:360-367 (Pubitemid 36535366)
55. Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet 2004;19:438-443
56. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78-84. (Pubitemid 351263563)
57. Hospices Civils de Lyon. RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin. In: www.ClinicalTrials. gov. Bethesda, MD: National Library of Medicine (US). 2000-(cited 2009 Oct 31). Available from: http:// clinicaltrials.gov/ct2/show/NCT00485342? term=RIBAJUSTE&rank=1. NLM Identifier: NCT 00485342.
58. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008;61:919-924
59. Barreiro P, Rodriguez-Novoa S, Ruiz-Sancho A, et al. Comparison of hepatitis C virus early kinetics in HIV/HCV coinfected patients treated with weight-based ribavirin plus either pegIFN alpha-2a or pegIFN alpha 2b (poster 901). Presented at: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
60. Crespo M, Pou L, Esteban JI, et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 2007;12:1217-1223
61. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007;47:23-30. (Pubitemid 46817685)
62. Dominguez S, Cassard B, Duvivier C, et al. Early therapeutic drug monitoring of ribavirin predicts anemia and early virological response in HIVHCV- co-infected patients (poster 893). Presented at 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
63. Labarga P, Vispo ME, Barreiro P, et al. Rescue therapy with optimized peg-interferon plus ribavirin in HIV/HCV coinfected patients: critical role of ribavirin plasma levels in the pilot-NR trial (abstract 801). J Hepatol 2008;48(suppl 2):S299.
64. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008;80:1523-1529
65. Nunez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005;10:657-662 (Pubitemid 41224957)
66. Quioc JJ, Jullen V, Mallet V, Nalpas B, Pol S. Antiretroviral drugs reduce ribavirin levels in HIV-HCV-coinfected patients (poster 1269). Presented at: The Liver Meeting 2008: 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, October 31-November 4, 2008.
67. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005;39:401-405 (Pubitemid 41003783)
68. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001;8:287-292 (Pubitemid 32673741)
69. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-1580 (Pubitemid 36939631)
70. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-321
71. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768-774 (Pubitemid 46529043)
72. van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:721-725 (Pubitemid 351767641)
73. Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006;13:538-543 (Pubitemid 44100405)
74. Jain A, Vekatramanan R, Yelochan B, Kashyap R, Marcos A, Fung J. Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection. Transplant Proc 2005;37:3190-3196 (Pubitemid 41435659)
75. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-1038 (Pubitemid 47177137)
76. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007;13:1100-1108 (Pubitemid 47305028)
77. Sterneck M, Benten D, Stoehr C, Rogers X, Renders L, Fischer L. Ribavirin therapeutic drug monitoring in HCV reinfected liver transplant recipients treated with IFN/ribavirin (abstract 683). Am J Transplant 2006;6(suppl 2):298.
78. Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, et al. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients. Clin Pharmacol Ther 2008;84:573-580
79. Bruno R, Puoti M, Verucchi G, et al. Higher ribavirin doses are associated with a better RVR in HIV infected patients treated with pegylated interferon in combination with ribavirin for chronic hepatitis C (abstract 773). J Hepatol 2008;48(suppl 2):S288.
80. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002;24:701-708 (Pubitemid 35379522)
81. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004;43:140-146 (Pubitemid 38049445)
82. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006;62:710-714 (Pubitemid 44749548)
83. Sherman M, Bain V, Villeneuve JP, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Infect Dis Med Microbiol 2004;15:313-326 (Pubitemid 40065300)
84. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17:899-904. (Pubitemid 41192126)
85. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-1311
86. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-1458 (Pubitemid 39657021)
87. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-982